Dr Brandon Orr-Walker
|
|
- Shanon Garrett
- 5 years ago
- Views:
Transcription
1 Dr Brandon Orr-Walker Endocrinologist Clinical Head of Endocrinology and Diabetes Middlemore Auckland 17:45-18:10 What Can New Agents Offer Us?
2 Diabetes Management What do the new agents offer us? Brandon Orr-Walker August 2018
3 Outline Basic Premises and Assumptions Identifying the Opportunities Current state New treatment options, what new treatment options?
4 Basic Premises and Assumptions Only worth making the diagnosis if we are going to change the progression of disease Strong evidence base to reduce harm: Glycaemia BP Renal protection CVD risk Multifactorial management Early good control pays long term dividends We have people with diabetes at high risk of complications, and disparities exist Since 2003 majority of care for people with T2DM is to be in primary care Expertise in management is required to manage therapeutic challenge
5 Adapted from Stratton IM et al. on behalf of the UK Prospective Diabetes Study Group. BMJ 2000; 321:
6 Cumulative Incidence Hemoglobin A 1C Figure 5:DCCT-EDIC: Longterm Risk of Macrovascular Conventional Intensive Complications % 10% 8% 6% P < P < P = Any Cardiovascular Outcome 42% risk reduction P = 0.02 Conventional Intensive DCCT End of Randomized Treatment EDIC Year 1 EDIC Year Years Since Entry* *Diabetes Control and Complications Trial (DCCT) ended and Epidemiology of Diabetes Interventions and Complications (EDIC) began in year 10 (1993). Mean follow-up: 17 years. DCCT/EDIC Research Group. JAMA. 2002;287: Copyright 2002 American Medical Association. All rights reserved. Nathan DM, et al. N Engl J Med. 2005;353: Copyright 2005 Massachusetts Medical Society. All rights reserved.
7 Pathophysiologic Approach to Treatment of T2DM Metformin Thiazolidinediones _ Impaired Insulin Secretion Hyperglycemia TZDs GLP-1 analogues DPP-4 inhibitors Sulfonylureas Thiazolidinediones Metformin Increased Hepatic Glucose Production Decreased Glucose Uptake DeFronzo RA. Diabetes. 2009;58:
8
9 Clinical Inertia: Failure to advance therapy when recommended Brown JB et al. Diabetes Care 2004; 27(7):
10 CCM: Big Effort, Big Variation
11 Treatment Inertia= clinical inertia Two components: Clinician inertia Patient inertia Lack of access Health literacy Non-adherence Competing interests Refusal of treatment Uninformed/misinformed Well informed Lack of acceptable treatment options Many of the patient inertia factors can be clinician modified, and as healthcare professionals it is our role to do so to the best of our ability.
12 Treatment options in clinical inertia Two components: Clinician inertia Patient inertia Lack of access Health literacy Non-adherence Competing interests Refusal of treatment Uninformed/misinformed Well informed Lack of acceptable treatment options Many of the patient inertia factors can be clinician modified, and as healthcare professionals it is our role to do so to the best of our ability.
13 Acceptability of Treatment Options Patient (acceptability) Side effects Misconceptions Belief Experience of success ( especially for uptitration) Response of health care team Healthcare team Resource Competency Belief Promotion Treatment options per se Funding Advantages beyond targeted indication (external gains) Cost
14
15 Management of glycaemic control (NZ) Lifestyle modificatio n If above target First line drug therapy If above target >3 months Second line drug therapy If above target >3 months If above target (HbA 1c mmol/mol [ %] or as individually agreed) Third line drug therapy Food, physical activity and behavioural strategies Metformin Gastrointestinal tolerance may be improved by If metformin gradual introduction Stop if not tolerated egfr <30 ml/min/1.73m 2 or Review medication adherence and contraindicate dose optimisation d Sulphonylurea Review medication adherence and dose optimisation Insulin 4 Review medication adherence and dose optimisation If measured HbA 1c does not meet or closely approach agreed target within 3 months, or if patient is symptomatic, drug therapy should be considered Sulphonylurea Educate the person on the possibility of hypoglycaemia Acarbose therapy 1 Thiazolidinedione (pioglitazone) 2, 3 If no congestive heart failure If at significant risk of hypoglycaemia Consider increased risk of fracture in women Guidance on the Management of Type 2 Diabetes 2011; available online at
16 Presentation title Date 16
17 Presentation title Date 17
18 Nice May 2017 Presentation title Date 18
19 ADA 2018 Standards of Care Presentation title Date 19
20 ADA 2018 Standards of Care Presentation title Date 20
21 Individualising HbA 1c goals Psycho- Bio- Patientcentred care -social Inzucchi et al. Diabetes Care 2012;35:
22 Presentation title Date 22
23 No new DKD-specific treatment in the last 15 years RAAS blockade 23 High blood pressure identified as DKD risk IDNT 4, IRMA 2 5 Irbesartan No new DKD-specific treatment in the last 15 years Captopril 3 T1D factor T2D ß-blockers 1 Hydralazine 2 RENAAL 6 Losartan T2D
24 Cumulative % of patients with event RENAAL Patients Reaching the Primary Composite Endpoint* Risk reduction=16% P=0.02 Placebo Losartan 0 Placebo (n) 762 Losartan (n) Months In combination with open-label diuretic, calcium channel blocker, beta-blocker, alpha-blocker, *doubling of serum creatinine, end stage renal disease, Brenner and/or BM, centrally et al. acting N Engl agent J Med. death ;345(12): org 2001 Massachusetts Medical Society. All rights reserved
25 RENAAL
26 % of patients with event RENAAL First Hospitalization for Heart Failure % Risk reduction P= Placebo * (n) Months Losartan * (n) * In combination with open-label diuretic, calcium channel blocker, beta-blocker, alpha-blocker, Brenner and/or BM, centrally et al. acting N Engl agent J Med. 2001;345(12): org 2001 Massachusetts Medical Society. All rights reserved.
27 Presentation title Date 27 Newer agents Incretin Pathway SGLT2 inhibitors
28 Gila Monster Salivary product is GLP-1 agonist
29 Incretins Physiologically Regulate Insulin and Glucagon in a Glucose-dependent Manner GI tract Pancreas Ingestion of Food Release of Incretin Gut Hormones Active GLP-1 & GIP β-cells α-cells Glucose Dependent Insulin from β-cells (GLP-1 and GIP) Glucagon from α-cells (GLP-1) Glucose Dependent Glucose uptake and storage by muscles and other tissues Glucose output from the liver Physiologic glucose control Adapted from Kieffer TJ, Habener JF. Endocrine Reviews. 1999;20: ; Ahrén B. Curr Diabetes Report. 2003;2: ; Drucker DJ. Diabetes Care. 2003;26: ; Holst JJ. Diabetes Metab Res Rev. 2002;18: ; Drucker DJ. Expert Opin Investig Drugs. 2003;12: ; Ahrén B et al. Horm Metab Res. 2004;36:
30 GLP-1 Actions in Peripheral Tissue Heart Brain Neuroprotection Appetite Gastric emptying Stomach Stomach Cardioprotection Cardiac output GI Tract GLP-1 Liver _ Insulin secretion β-cell neogenesis Glucose production Drucker DJ. Cell Metab. 2006;3: Muscle + Glucose Uptake β-cell apoptosis Glucagon secretion
31 Levels of Active Incretins GLP-1 and GIP Are Increased by DPP-4 Inhibition Meal Intestinal GIP and GLP-1 release DPP-4 Enzyme DPP-4 Inhibitor GIP-(1-42*) GLP-1(7-36)* Active XRapid Inactivation GIP-(3-42)* GLP-1(9-36)* Inactive GIP and GLP-1 Actions *Refers to amino acid number. Deacon CF et al. Diabetes. 1995;44:
32 Side Effects: GLP-1 Receptor Agonists and DPP-4 Inhibitors GLP-1 Receptor Agonists DPP-4 Inhibitors Side effects Gastrointestinal Well tolerated Weight Administration Other cardiac risk factors > 85% patients lose weight Twice-daily injection Triglycerides HDL Blood pressure Weight neutral Oral, once daily Unknown Davidson JA. Cleve Clin J Med. 2009;76(suppl5):S28-S38.
33 Presentation title Date 33 DPP4 inhibitors Januvia (Sitagliptin) Galvus (Vildagliptin) Onglyza (Saxagliptin) Tradjenta (Linagliptin) (NZ Approved) (NZ Approved) (NZ Approved)
34 Presentation title Date 34
35 GLP-1 Receptor Agonists First-in-class (exenatide) approved in 2005 Augment insulin secretion Inhibit glucagon secretion Lower fasting glucose and improve postprandial glucose profile Schnabel CA, et al. Vasc Health Risk Manag. 2006;2:69-77.
36 Presentation title Date Slide no 36 GLP 1 agonists exenatide (Byetta/Bydureon), approved in 2005/2012 (NZ Approved) liraglutide (Victoza, Saxenda), approved 2010 lixisenatide (Lyxumia), approved in 2016 (NZ not available) albiglutide (Tanzeum), approved in 2014 dulaglutide (Trulicity), approved in 2014 semaglutide (Ozempic), approved in 2017.
37 Change in A1c (%) Exenatide Sustained A1c Reductions Over 82 Weeks 82-Week Completer 82-Week ITT Mean Baseline A1c 8.3% 8.4% 0.0 Placebo-controlled -0.5 Open-label extension (All patients 10 mg BID) -0.8% ± 0.1% % ± 0.1% Blonde L, et al. Diabetes Obes Metab. 2006;8: Time (week) Blonde L, et al. Diabetes Obes Metab. 2006;8: wk completer, N = 314; 82-wk ITT, N = 551; Mean ±SE.
38 Durability of Exenatide: Weight Blonde L, et al. Diabetes Obes Metab. 2006;8:
39 A1c Level (%) Change in Body Weight (kg) Exenatide vs Insulin Glargine as Add-on Therapy in T2DM Exenatide group (n = 275) Insulin glargine group (n = 260) Heine RJ, et al. Ann Intern Med. 2005;143: * * * * * *
40 Patients with an event (%) LEADER trial: Primary Outcome First occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke in the time-to-event analysis in patients with type 2 diabetes and high CV risk Hazard ratio, 0.87 (95% CI, ) P<0.001 for noninferiority P=0.01 for superiority 10 5 Placebo Liraglutide Months since randomisation Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial Adapted from: Marso SP et al., NEJM 2016
41 LEADER trial: Death from Cardiovascular Causes Patients with an event (%) 20 Hazard ratio, 0.78 (95% CI, ) P= Placebo Liraglutide Months since randomisation Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial Adapted from: Marso SP et al., NEJM 2016
42 Presentation title Date 42 SGLT-2 inhibitors canagliflozin (Invokana) first for FDA approval (2013) dapagliflozin (Forxiga/Farxiga) (NZ approved) empagliflozin (Jardiance)
43 SGLT, sodium glucose cotransporter. Gerich JE. Diabet Med 2010;27:136 Renal glucose reabsorption in patients with hyperglycaemia 43 Filtered glucose load >180 g/day SGLT 2 When blood glucose increases above the SGLT 1 renal threshold (>~10 mmol/l or >180 mg/dl), the capacity of SGLTs is exceeded, resulting in urinary glucose
44 SGLT, sodium glucose cotransporter. *Loss of ~ 80 g of glucose per day = 240 cal/day. Bakris GL et al. Kidney Int 2009;75;1272 Empagliflozin increases urinary glucose excretion via SGLT2 inhibition 44 Filtered glucose load >180 g/day SGLT 2 SGLT2 inhibit ~90% or SGLT 1 compensate SGLT2 inhibitors reduce glucose reabsorption in the proximal tubule, leading to urinary glucose excretion* and osmotic diuresis ~ 80 g
45 GFR, glomerular filtration rate Cherney D et al. Circulation 2014;129: Renal anatomy and physiology Afferent arteriole Vasoconstriction decreases GFR Efferent arteriole Vasoconstriction increases GFR Bowman s capsule Key Flow of blood Flow of filtrate Proximal convoluted tubule
46 NO, nitric oxide; RAAS, renin angiotensin-aldosterone system Burke M et al. Current Vascular Pharmacology 2014;12:845 The kidney auto-regulates glomerular filtration by moderating afferent and efferent arteriole tone Afferent arteriole Prostaglandin s NO Efferent arteriole RAAS 46 Flow of filtrate Increased filtration
47 SGLT, sodium glucose cotransporter; GFR, glomerular filtration rate. Adapted from: Cherney D et al. Circulation 2014;129:587 Skrtic M et al. Diabetologia 2014;57:2599 Empagliflozin exerts a hemodynamic effect within the kidney 47 By restoring the Tubulo-Glomerular Feedback (TGF), empagliflozin increases the afferent arteriole tone, thereby lowering glomerular hypertension Action: narrowing Clinical implications: SGLT2 inhibition Afferent arteriole narrowing Glomerular pressure decreases Early clinical marker: Initial dip in GFR Reduction of albuminuria
48 Mean GFR (ml/min/1.73 m 2 ) Note: Data from two different studies. ACEi, angiotensin-converting enzyme inhibitor; GFR, glomerular filtration rate. 1. Sochett E et al. J Am Soc Nephrol 2006;17:1703; 2. Cherney D et al. Circulation 2014;129:587 Empagliflozin effect on glomerular hyperfiltration shows similar magnitude as ACE inhibitor Baseline ACEi Empagliflozin ml/min ml/min ACEi Empagliflozin
49 Patients received JARDIANCE or placebo on top of standard of care for CV and T2D management 1 Standard of care + Placebo (n=2333) Randomised Standard of care + JARDIANCE and treated 10 mg (n=2345) (n=7020) Pooled Standard of care + JARDIANCE 25 mg (n=2342) Adults with T2D Established CV disease (CAD, PAD, MI or stroke) HbA 1c 7-10% egfr >30 ml/min/1.73m 2# Glucose-lowering therapy was to remain unchanged for the first 12 weeks The trial was to continue until at least 691 patients experienced an adjudicated primary outcome event Standard of care included antihypertensives, lipid-lowering agents, anticoagulants and glucose-lowering therapies. 1 Data from both doses of JARDIANCE were pooled for statistical analysis versus placebo # JARDIANCE can be used be used down to an egfr of 45 Slide ml/min/1.73m 3 of 20 2
50 CV risk factor profile at study entry 1 Patient characteristics 63 Age (years) 57% Pt with T2D duration >10 years 30.6 BMI (kg/m 2 ) 105 Waist circumference (cm) Previous CV events 76% Coronary artery disease 47% History of MI 23% History of stroke 10% Heart failure 21% Peripheral artery disease Data are mean or %. BMI, body mass index. 1. Zinman B et al. N Engl J Med 2015;373: Slide 4 of 20
51 Patients treated appropriately for their CV risk 1 Glycaemic management Blood pressure management Lipid management Anti-platelet and anti-coagulant therapies Mean HbA 1c 8.1% Metformin use 74% Insulin use 48% SBP/DBP, mmhg 136/77 Any BP-lowering drug 95% ACEi/ARB 81% Any lipid lowering drug 81% Statins 77% Any anti-platelet / anticoagulant drug 89% Acetylsalicylic acid 83% In 7020 patients treated with 1 dose of study drug. SBP, systolic blood pressure; DBP, diastolic blood pressure. 1. Zinman B et al. N Engl J Med 2015;373: Slide 5 of 20
52 Patients with event (%) CV death JARDIANCE reduced the relative risk of CV death by 38% vs placebo on top of 9 Early standard * of sustained care patients # response with T2D and established CV disease (CAD, PAD, MI or stroke) Standard of care + HR Placebo p< Months Adapted from Zinman B et al *Within 6 months from start. # Up to 48 months from start. CV death was a pre-specified secondary endpoint. Cumulative incidence function. HR, hazard ratio The absolute risk for CV death was 5.9% in patients receiving standard of care plus placebo and was reduced to 3.7% in patients receiving standard of care plus JARDIANCE (p<0.001) Zinman B et al. N Engl J Med 2015;373: Standard of care + JARDIANCE Results achieved on top of standard of care Antihypertensives Lipid lowering agents Anticoagulants Glucose lowering agents Slide 8 of 20
53 Patients with event (%) All-cause mortality JARDIANCE reduced the relative risk of all-cause mortality by 32% JARDIANCE is not indicated to reduce all-cause mortality vs placebo on top of standard of care in patients with T2D and established CV disease (CAD, PAD, MI or stroke) Early 14 * 1 and sustained # response HR 0.68 p< Months *Within 6 months from start. # Up to 48 months from start. Adapted from Zinman B et al All cause mortality was a pre-specified secondary endpoint. Kaplan-Meier estimate. HR, hazard ratio The absolute risk for all-cause mortality was 8.3% in patients receiving standard of care plus placebo and was reduced to 5.7% in patients receiving standard of care plus JARDIANCE (p<0.001) Zinman B et al. N Engl J Med 2015;373: Standard of care + Placebo Standard of care + JARDIANCE Results achieved on top of standard of care Antihypertensives Lipid lowering agents Anticoagulants Glucose lowering agents Slide 10 of 20
54 Patients with event (%) Hospitalisation for heart failure JARDIANCE reduced the relative risk of hospitalisation for heart failure by 35% vs placebo on top of standard of care in patients with T2D and established CV disease (CAD, JARDIANCE PAD, is MI not or indicated stroke) to 1 reduce hospitalisation for heart failure 7 Early * and sustained # response Standard of care + Placebo HR 0.65 p= Months Adapted from Zinman B et al *Within 6 months from start. # Up to 48 months from start. Hospitalisation for heart failure was a pre-specified secondary endpoint. Cumulative incidence function. HR, hazard ratio The absolute risk for hospitalisation for heart failure was 4.1% in patients receiving standard of care plus placebo and was reduced to 2.7% in patients receiving standard of care plus JARDIANCE (p<0.002) Zinman B et al. N Engl J Med 2015;373: Standard of care + JARDIANCE Results achieved on top of standard of care Antihypertensives Lipid lowering agents Anticoagulants Glucose lowering agents Slide 12 of 20
55 Number needed to treat (NNT) to save 1 life 4S 1 HOPE 2 Simvastatin 1 for 5.4 years 30 Ramipril 2 for 5 years 56 EMPA-REG OUTCOME 3 JARDIANCE 3 for 3.1 years 39 In high CV risk 5% diabetes, 26% hypertension In high CV risk 38% diabetes, 46% hypertension T2D with established CV disease (CAD, PAD, MI or stroke) on top of standard of care 92% hypertension Pre-statin era Pre-ACEi/ARB era <29% statin > 80% ACEi/ARB > 75% statin No w Standard of care included antihypertensives, lipid-lowering agents, anticoagulants and glucose-lowering therapies. 3 ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers, 1. 4S investigators. Lancet 1994;344: HOPE investigators, N Engl J Med 2000;342: Zinman B et al. N Engl J Med 2015;373: Slide 14 of 20
56 JARDIANCE slowed the progression of renal indicators in the EMPA-REG OUTCOME study in patients with T2D and established CV disease (PAD, CAD, MI or stroke) on top of standard of care 1*# # JARDIANCE is not indicated to prevent decline in renal function *Incident or worsening nephropathy analysed in patients who did not have macroalbuminuria at baseline. Modified intention to treat analyses in patients who received 1 study drug. Defined as progression to macroalbuminuria (urinary albumin to-creatinine ratio, >300mg of albumin per gram of creatinine); a doubling of the serum creatinine level, accompanied by an egfr of 45 ml/min/1.73m 2, as calculated by the Modification of Diet in Renal Disease (MDRD) formula; the initiation of renal-replacement therapy; or death from renal disease. Death due to renal disease: 3 events on JARDIANCE and 0 on placebo. Slide 15 of 20 Standard of care included antihypertensives, lipid-lowering agents, anticoagulants and glucose-lowering agents. 2
57 Presentation title Date 57 Summary Diabetes prevalence is growing Strong evidence base or reduced complications with optimal management There remain substantive numbers of people not at/near target for management Therapy needs to multifactorial and introduced progressively and incrementally to manage diabetes over time reflecting the progressive pathogenesis Newer therapies offer several advantages including convenience, side effect profile and are showing superiority in studied populations for renal and CVD endpoints above standard care Maori and Pacifica are at particularly high risk for CVD and renal harm from diabetes Cost is an issue, but largely because of the high numbers with diabetes with suboptimal control currently, thus cost is likely to come with substantive benefit.
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationANGELA GINN-MEADOW RD LDN CDE
DIABETES DRUGS & TRENDS MADE SIMPLE PHARMD TO RD ANGELA GINN-MEADOW RD LDN CDE OBJECTIVES At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationNew Approaches for Treating Challenging Patients with Diabetes
New Approaches for Treating Challenging Patients with Diabetes Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationType 2 Diabetes Novel Therapies and Difficult Cases
Type 2 Diabetes Novel Therapies and Difficult Cases Matt Dowell, DO Type 2 Diabetes - An Epidemic Is Here 1 Age-Adjusted Prevalence of Diagnosed Diabetes Among US Adults 2005 Missing data
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More information